This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Alzheimer’s Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results


Meinert, Curtis L., McCaffrey, Lee D., Breitner, John C. S.


Alzheimer's & Dementia: The Journal Of The Alzheimer's Association, Volume: 5, No.: 2, Pages.: 93-104

Year of Publication



Background: The Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT) was designed to address whether non-steroidal anti-inflammatory drugs (NSAIDs) can prevent or delay the onset of Alzheimer’s disease (AD).; Methods: ADAPT was a randomized, double-placebo-controlled, multicenter chemoprevention trial conducted at six U.S. dementia research clinics. At entry, participants were required to test “normal” on a battery of cognitive tests and to be age 70+ with a family history of Alzheimer-like dementia. Persons were randomly assigned to 200 mg b.i.d. celecoxib (Celebrex, Pfizer), 220 mg b.i.d. naproxen sodium (Aleve, Bayer), or placebo. The primary outcome measure was AD. Secondary outcome measures were cognitive decline and measures related to safety of the treatments when used long term. ADAPT was designed to detect a 30% reduction in AD incidence with 80% power. The estimated sample size requirement was 2,625.; Results: Enrollment began in March 2001 and ended in December 2004 when treatments were suspended because of concerns regarding cardiovascular safety of the treatments. Followup ranged from 1 to 46 months. The achieved enrollment was 2,528. Recruitment was achieved primarily via mailings to people aged 70+ living in the catchment areas of the six field sites.;

Bibtex Citation

@article{2009, doi = {10.1016/j.jalz.2008.09.004}, url = {}, year = 2009, month = {mar}, publisher = {Elsevier {BV}}, volume = {5}, number = {2}, pages = {93--104}, title = {Alzheimer{textquotesingle}s Disease Anti-Inflammatory Prevention Trial: Design, methods, and baseline results}, journal = {Alzheimer{textquotesingle}s {&} Dementia} }


administration & dosage, adverse effects, aged, aged, 80 and over, alzheimer disease, brain, celecoxib, cognition disorders, drug effects, drug therapy, encephalitis, female, humans, male, metabolism, methods, naproxen, neuropsychological tests, nsaids, outcome assessment (health care), patient selection, physiopathology, placebos, prevention & control, pyrazoles, research design, sodium, sulfonamides, time, treatment outcome

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Randomised Controlled Trial

Type of Outcomes



Hospital Outpatient Care

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions